CMC Biologics and OncoSynergy have entered an agreement for process development and GMP manufacture of OS2966, a potential treatment for Ebola. 0OS2966 is a monoclonal antibody designed to inhibit a major cellular adhesion receptor (CD29) that’s fundamental for progression of aggressive and resistant cancer, and was granted orphan drug designation by the FDA for the treatment of glioblastoma. Previous studies have suggested blocking CD29 could halt Ebola’s spread in the body. 0OS2966 is a...